Basel, December 3, 2007 - Lonza announces a worldwide price increase of 15-17% for Niacin and Niacinamide for food and dietary supplement applications.
This increase is necessary due to the continued increase of raw materials, energy and transportation costs.
This increase will affect all non-contract customers and other customers as their contracts permit.
The new prices will come into effect on 1 January 2008.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of pharmaceutical active ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2006 Lonza had sales of CHF 2.91 billion. Further information can be found at www.lonza.com.